Company Description
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics for improving outcomes for patients with difficult-to-treat liver and pancreatic cancers.
It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
The company also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.
TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Mary Szela |
Contact Details
Address: 6272 West 91st Avenue Westminster, Colorado 80031 United States | |
| Phone | (888) 321-5212 |
| Website | trisaluslifesci.com |
Stock Details
| Ticker Symbol | TLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826667 |
| CUSIP Number | 89680M101 |
| ISIN Number | US89680M1018 |
| Employer ID | 85-3009869 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mary T. Szela B.S.N., M.B.A. | Chief Executive Officer, President and Director |
| James E. Young | Chief Financial Officer, Secretary and Treasurer |
| Lori Ann Santamaria | Vice President of Operations |
| Jennifer L. Stevens J.D. | Chief Regulatory Officer |
| Dr. Richard B. Marshak M.B.A., MBA, VMD | Chief Commercial Officer |
| Jodi Devlin | Chief of Clinical Strategy and Operations |
| Dr. Bryan F. Cox Ph.D. | Chief of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | D | Notice of Exempt Offering of Securities |
| May 2, 2025 | EFFECT | Notice of Effectiveness |
| May 2, 2025 | SCHEDULE 13D/A | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2025 | 425 | Filing |
| Apr 30, 2025 | 8-K | Current Report |
| Apr 28, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 25, 2025 | S-3 | Registration statement under Securities Act of 1933 |